Cytarabine

The SelleckChem library from the Molecular Screening Facility at the Wistar Institute was used for initial screens. However, once hits were identified, additional material was purchased for further testing. Mubritinib (S2216), Carmofur (S1289), Erlotinib HCl (S1023), NSC-207895 (S2678), OSI-420 (S2205), Emodin (S2295), TAK-285 (S2784), and Deguelin (S8132) were purchased from SelleckChem. Linifanib (M15676), Regorafenib (R16040), and Afatinib (G-7208) were purchased from AChemBlock. Adrucil (228440010) and Cytarabine (449561000) were purchased from Acros Organics. Lenalidomide (6305/100) and Dopamine HCl (3548/50) were purchased from Tocris Bioscience. Dacomitinib (PZ0330) and Rotenone (R8875) were purchased from Sigma. Rapamycin (J62473) was purchased from Alfa Aesar.

Primary Human CD34⁺ cells from Yale Cooperative Center of Excellence in Hematology (YCCEH, Yale University) were immunomagnetically isolated for CD34⁺ as described^{55 (link)} from granulocyte colony stimulating factor–mobilized peripheral blood mononuclear cells from healthy donors. Primary human T-cells were received from UNC Chapel Hill; StemSpam, Methocult Media, MesenCult MSC Basal Media, ACF, MyeloCult (H5100) media, and BIT 9500 serum substitute were purchased from stem cell technologies (Vancouver, Canada). Growth factors IL-3, IL-6, FLT3L, SCF, IL-2, IL-7, and IL-15 were all obtained from ConnStem (CT, USA). Gilteritinib (MW 552.7) was purchased from Medchemexpress (NJ, USA), azacytidine (MW 244.2) from Selleck Chemical (TX, USA), arsenic trioxide (MW 197.8) from Alfa Aesar (MA, USA), cytarabine (MW 243.2) from Acros Organics (NJ, USA), and imatinib (MW 589.7) and U0126 (MW 380.5) from MilliporeSigma (MA, USA). Vibrant CM-DiI was purchased from Invitrogen (CA, USA).